AccessClosure of Mountain View, CA is releasing a new version of its Mynx vascular closure device, the Mynx Cadence. When contacted by Medgadget, the company representative told us that the key differences between the Mynx Vascular Closure Device and St. Jude’s popular Angio-Seal system is in the way the femoral artery is closed and in the chemical composition of the sealant. For one, Angio-Seal has a sandwich structure, with a bioabsorbable intravascular anchor. Mynx Cadence, on the other hand, is a complete extravascular closure device. The sealant composition difference between two devices is also important, according to the company. While Angio-Seal uses collagen, a bioactive thrombogenic agent, Mynx deploys inert polyethylene glycol (PEG). And, finally, while Angio-Seal is advertised to dissolve within 60 to 90 days, Mynx is said to be entirely gone within 30 days.
Here are the design changes in the new Mynx Cadence:
Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy. A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling. Additionally, a single marker on the advancer tube removes any guesswork around sealant compression. Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation. These changes result in more consistent sealant delivery every time.
The Mynx Vascular Closure Device utilizes a conformable, waterâ€soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery.
Animation demonstrating the previous generation Mynx:
Press release: AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device… (.pdf)
AccessClosure …







Ports or portacaths are widely used in hematology and oncology patients for easy vascular access. However, not all of them can withstand power injection of contrast media and asking patients which port they have can be an unreliable method at times. That is why Smiths Medical has launched new versions of its implantable ports with radio-opaque identifiers which can be seen on X-ray and CT scout scans. The letters C and T are embedded into the top of the port, which, the company proudly announces, prevents them from being read backwards like might happen with other manufacturers’ products. Indeed that always confused us completely! Nevertheless, this is a nice little tweak to a useful product.
Viveve, from Palo Alto, CA, has received approval for a condition we never heard of before: vaginal laxity. On the other hand, of course, in this age where vaginoplasties are quickly becoming as normal as nose jobs, we should not be really surprised. The device uses radiofrequency to treat laxity of the vaginal introitus after childbirth, to improve the female sexual function. The system consists of a RF generator, a hand piece and single-use disposable tips. The procedure can be performed without anesthesia in approximately 30 minutes. According to studies cited by the company in the press release, women have reported improved feelings of vaginal tightness at several months after treatment (no words about male satisfaction though). Bingo, a new market has been created!
Researchers from Rice University and Baylor College of Medicine have developed a method to grow blood vessels in a laboratory. The investigators used biomimetic polyethylene glycol hydrogels embedded with a growth factor called BB (PDGF-BB) to spur angiogenesis, and are now working on a way to guide the formation of vasculature for specific applications.
Researchers at the University of North Carolina-Chapel Hill have created particles that mimic red blood cells in size, shape and flexibility. Using a fabrication process called Particle Replication in Non-wetting Templates, or PRINT, 6 μm hydrogel discs are produced that can circulate through the body for 93 hours before they are excreted, compared to about 3 hours for the stiffer particles that are currently being researched. Other functions, such as oxygen transport or therapeutic drug delivery, have not been tested, but these flexible particles are a major improvement because red blood cells naturally deform in order to pass through capillaries. These new flexible hydrogel particles are also able to move through the body in a similar fashion, and are removed from the body by the spleen, the organ that typically removes red blood cells.

Varian Medical Systems out of Palo Alto, California received FDA 510(k) clearance for its proton beam radiation therapy system. The certification means that hospitals do not need to seek individual clearances to install the Varian system.






